US 9,981,939 B2 · Compounds and uses thereof for the modulation of hemoglobin

Abstract

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Claims7

Dependent claims

A compound selected from:

or
a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application

14/776,603Filed 10 Mar 2014 · continuation in part

Priority

15 Mar 2013

Published

US 2016/0046613 A118 Feb 2016

Granted

29 May 2018

Term ends

Not estimatedThe source records don’t support an estimate.

Classification36 codes

C07D 401/04
Containing two hetero rings: directly linked by a ring-member-to-ring-member bond
A61K 8/4913
With one nitrogen as the only hetero atom: having five membered rings, e.g. pyrrolidone carboxylic acid
A61K 31/445
Non condensed pyridines; Hydrogenated derivatives thereof: non condensed piperidines, e.g. piperocaine
A61K 31/5375
Having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines: 1,4-Oxazines, e.g. morpholine

Family

Application13/815,770Parent of this continuation-in-part · filed 15 Mar 2013

Application61/905,803Us provisional application · filed 18 Nov 2013

Application61/905,802Us provisional application · filed 18 Nov 2013

US 2016/0046613 A1Pre-grant publication · published 18 Feb 2016

US 9,422,279 B2Parent of this continuation-in-part

US 2014/0275152 A1Published application

US 9,981,939 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

14/776,603Filed 10 Mar 2014 · continuation in part

Priority

15 Mar 2013

Published

US 2016/0046613 A118 Feb 2016

Granted

29 May 2018

Term ends

Not estimatedThe source records don’t support an estimate.

Classification36 codes

C07D 401/04
Containing two hetero rings: directly linked by a ring-member-to-ring-member bond
A61K 8/4913
With one nitrogen as the only hetero atom: having five membered rings, e.g. pyrrolidone carboxylic acid
A61K 31/445
Non condensed pyridines; Hydrogenated derivatives thereof: non condensed piperidines, e.g. piperocaine
A61K 31/5375
Having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines: 1,4-Oxazines, e.g. morpholine

Family

Application13/815,770Parent of this continuation-in-part · filed 15 Mar 2013

Application61/905,803Us provisional application · filed 18 Nov 2013

Application61/905,802Us provisional application · filed 18 Nov 2013

US 2016/0046613 A1Pre-grant publication · published 18 Feb 2016

US 9,422,279 B2Parent of this continuation-in-part

US 2014/0275152 A1Published application

US 9,981,939 B2This patent

From the US filing history. Foreign family members aren’t listed.

Compounds and uses thereof for the modulation of hemoglobin

Life of this patent

Abstract

Claims7

Compounds and uses thereof for the modulation of hemoglobin

Life of this patent

Abstract

Claims7